TABLE 6.
Clinical characteristics between patients with (n=40) and without HCC recurrence (n=296)
| Characteristics | HCC recurrence, n = 40 | No HCC recurrence, n = 296 | P |
|---|---|---|---|
| Median age (IQR) | 59.4 (55.4–62.1) | 57.9 (53.2–62.9) | 0.21 |
| Male (%) | 25 (62.5%) | 233 (78.7%) | 0.02 |
| Liver disease (%) | |||
| HCV | 20 (50.0%) | 178 (60.1%) | 0.18 |
| HBV | 11 (27.5%) | 82 (27.7%) | |
| Other | 9 (22.5%) | 36 (12.2%) | |
| HCC number at listing | |||
| 1 | 25 (62.5%) | 231 (78.0%) | 0.003 |
| 2 | 9 (22.5%) | 55 (18.6%) | |
| 3 | 6 (15.0%) | 10 (3.4%) | |
| Type of LRT received | |||
| TACE | 34 (85.0%) | 241 (81.4%) | 0.58 |
| RFA | 21 (52.5%) | 111 (37.5%) | 0.07 |
| Median number of LRT received (IQR) | 2 (1–2) | 1 (1–2) | 0.06 |
| Median AFP at diagnosis (ng/mL) (IQR) | 30.0 (5–108) | 13.0 (5–66) | 0.13 |
| AFP always <20 ng/mL | 13 (32.5%) | 137 (46.3%) | 0.10 |
| Median AFP at transplant (IQR) | 31.1 (5–144) | 8.0 (4–32) | 0.007 |
| Median AFP slope (ng/mL per month) | −0.03 (−1.07–0.84) | −0.16 (−1.60–0.11) | 0.15 |
| Explant tumor grade | |||
| No viable tumor | 9 (22.5%) | 129 (43.6%) | 0.002 |
| Well differentiated | 5 (12.5%) | 67 (22.6%) | |
| Moderately diffentiated | 22 (55.0%) | 83 (28.0%) | |
| Poorly differentiated | 4 (10.0%) | 17 (5.7%) | |
| Microvascular invasion | 14 (35.0%) | 9 (3.0%) | <0.001 |
| Explant tumor stage beyond Milan | 18 (45.0%) | 35 (11.8%) | <0.001 |